MDM2 inhibitor and a platinum compound for cancer treatment
US-11850239-B2 · Dec 26, 2023 · US
Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
US12194024B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12194024-B2 |
| Application number | US-202017277562-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 24, 2020 |
| Priority date | Jul 26, 2019 |
| Publication date | Jan 14, 2025 |
| Grant date | Jan 14, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are pharmaceutical compositions comprising an MDM2 inhibitor and one or more anti-cancer agents for preventing and/or treating diseases, such as cancer. Methods for preventing and/or treating diseases, such as cancer, comprising administering to the patient in need thereof with the pharmaceutical compositions are also provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition for preventing and/or treating cancer, comprising an MDM2 inhibitor and an anti-cancer agent and optionally a pharmaceutically acceptable carrier, diluent, or excipient wherein said MDM2 inhibitor is compound 2 or a pharmaceutically acceptable salt or solvate thereof: wherein said anti-cancer agent is a combination of Dabrafenib and Trametinib. 2. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition or said MDM2 inhibitor or said anti-cancer agent is in the forms of tablet, capsule, granule, syrup, powder, troche, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol, ointment, cream and injection. 3. A kit comprising: (a) a first component in a first container, wherein said first component comprises the pharmaceutical composition comprising MDM2 inhibitor and optionally a pharmaceutically acceptable carrier, diluent or excipient, wherein said MDM2 inhibitor is compound 2 or a pharmaceutically acceptable salt or solvate thereof: and (b) a second component in a second container, wherein said second component comprises an anti-cancer agent and optionally a pharmaceutically acceptable carrier, diluent or excipient, wherein said anti-cancer agent is a combination of Dabrafenib and Trametinib. 4. The pharmaceutical composition of claim 1 , wherein the weight ratio of compound 2, Dabrafenib, and Trametinib is 50:30:1. 5. The kit of claim 3 , wherein the weight ratio of compound 2, Dabrafenib, and Trametinib is 50:30:1.
Assignees
Inventors
Classifications
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title
not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol · CPC title
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12194024B2 cover?
- Provided herein are pharmaceutical compositions comprising an MDM2 inhibitor and one or more anti-cancer agents for preventing and/or treating diseases, such as cancer. Methods for preventing and/or treating diseases, such as cancer, comprising administering to the patient in need thereof with the pharmaceutical compositions are also provided.
- Who is the assignee on this patent?
- Ascentage Pharma Suzhou Co Ltd, Ascentage Pharma Group Corp Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K45/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).